Clinical trial
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
NCT00063388 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00063388 |
|---|---|
| Title | Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer |
| Official title | A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Biological |
| Interventions | Cetuximab |
| Enrollment | 66 |
| Start date | May 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jun 27, 2003 |
| Last update posted | Apr 12, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: